Intraosseous Injection of Flurbiprofen Axetil for Postoperative Analgesia in Joint Arthroplasty
This single-center, prospective, randomized, double-blind, double-dummy controlled trial aims to evaluate the efficacy and safety of intraosseous versus intravenous flurbiprofen axetil for postoperative pain management in patients undergoing joint arthroplasty.
A total of 240 patients aged 65-80 years undergoing primary unilateral total knee arthroplasty, unicompartmental knee arthroplasty, total hip arthroplasty, or hemiarthroplasty will be enrolled. Participants will be stratified according to surgical procedure and randomly assigned in a 1:1 ratio to receive either intraosseous flurbiprofen axetil with intravenous saline placebo or intravenous flurbiprofen axetil with intraosseous saline placebo. The dose of flurbiprofen axetil will be 50 mg in both groups.
The primary outcome is postoperative pain intensity at rest, assessed using the Visual Analog Scale (VAS) at predefined time points from 1 hour to 6 weeks after surgery. Secondary outcomes include pain during movement, cumulative opioid consumption within 72 hours, length of hospital stay, joint functional recovery, patient satisfaction, patient-controlled analgesia utilization, and adverse events.
This study aims to determine whether intraosseous administration of flurbiprofen axetil provides effective and safe postoperative analgesia compared with conventional intravenous administration following joint arthroplasty.
調査の概要
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Hua Luo, Dr.
- 電話番号:0576-85190463
- メール:luohua66ry@163.com
研究場所
-
-
Zhejiang
-
Linhai、Zhejiang、中国、317000
- 募集
- No. 150 Ximen Road
-
コンタクト:
- Hua Luo
- 電話番号:0576-85190463
- メール:luohua66ry@163.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Adults aged 65 to 80 years, regardless of sex.
- Patients scheduled to undergo unilateral joint arthroplasty.
- Patients scheduled for elective surgery with standardized surgical procedures and prosthesis types, consistent with the postoperative analgesia protocol of this study.
- Patients scheduled to receive general anesthesia.
- Patients who are able to understand the study objectives, procedures, and potential risks, voluntarily provide written informed consent, and cooperate with postoperative assessments, including Visual Analog Scale (VAS) pain scores, functional assessments, and patient satisfaction evaluations.
Exclusion Criteria:
- Known hypersensitivity to flurbiprofen, other nonsteroidal anti-inflammatory drugs (NSAIDs), or contraindications to opioids or other medications used in the study.
- Contraindications to NSAID use, including peptic ulcer disease, gastrointestinal bleeding, severe hepatic or renal impairment, or coagulation disorders.
- Severe cardiovascular, hepatic, renal, hematological, or central nervous system diseases that may prevent patients from tolerating general anesthesia or analgesic medications.
- Recent history of gastrointestinal bleeding or active peptic ulcer disease.
- Severe infection, immunodeficiency, or risk of sepsis.
- Psychiatric disorders or cognitive impairment that prevent reliable assessment of postoperative pain intensity or patient satisfaction.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Intraosseous Flurbiprofen
Participants will receive a total dose of 50 mg flurbiprofen axetil via intraosseous administration. For knee arthroplasty, the medication will be administered into the distal femoral and proximal tibial bone cavities. For hip arthroplasty, the medication will be administered into the bone cavity near the greater trochanter. |
Flurbiprofen axetil 50 mg will be administered intraosseously into the distal femoral and proximal tibial bone cavities for knee arthroplasty or near the greater trochanter for hip arthroplasty. Flurbiprofen axetil 50 mg will be administered intravenously. |
|
アクティブコンパレータ:Intravenous Flurbiprofen Axetil
Participants will receive 50 mg flurbiprofen axetil through intravenous administration. |
Flurbiprofen axetil 50 mg will be administered intraosseously into the distal femoral and proximal tibial bone cavities for knee arthroplasty or near the greater trochanter for hip arthroplasty. Flurbiprofen axetil 50 mg will be administered intravenously. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Visual Analog Scale
時間枠:At 1, 2, 3, 4, 5, 6, 12, 24, 48, and 72 hours after surgery; postoperative day 7; and postoperative weeks 2 and 6.
|
Postoperative pain intensity at rest will be assessed using the Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity. |
At 1, 2, 3, 4, 5, 6, 12, 24, 48, and 72 hours after surgery; postoperative day 7; and postoperative weeks 2 and 6.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Cumulative Opioid Consumption Within 72 Hours
時間枠:up to 72 hours post-surgery
|
The cumulative dose of opioid analgesics administered during the first 72 hours after surgery will be recorded. Opioid consumption will be converted into morphine milligram equivalents to facilitate comparison between the two treatment groups. |
up to 72 hours post-surgery
|
|
Length of Hospital Stay
時間枠:From the date of hospital admission to the date of hospital discharge, assessed up to 30 days.
|
The length of hospital stay will be calculated as the number of days from hospital admission to hospital discharge. The duration of hospitalization will be compared between the two treatment groups. Unit: days. |
From the date of hospital admission to the date of hospital discharge, assessed up to 30 days.
|
|
Knee Society Score
時間枠:At baseline (preoperative assessment), postoperative days 1, 3, and 7, and postoperative weeks 2 and 6.
|
Postoperative knee function will be evaluated using the Knee Society Score (KSS). Scores are recorded at predefined postoperative time points and compared between the two treatment groups to assess functional recovery. Unit: score. |
At baseline (preoperative assessment), postoperative days 1, 3, and 7, and postoperative weeks 2 and 6.
|
|
Patient Satisfaction With Postoperative Analgesia
時間枠:At hospital discharge.
|
Patient satisfaction with postoperative analgesia will be assessed using a 10-point Numerical Rating Scale (NRS), ranging from 0 (completely dissatisfied) to 10 (completely satisfied). Higher scores indicate greater satisfaction. Unit: score. |
At hospital discharge.
|
|
Cumulative PCA Analgesic Consumption
時間枠:From PCA initiation to PCA discontinuation, within the first 72 hours after surgery.
|
The cumulative amount of analgesic medication delivered through the patient-controlled analgesia (PCA) system will be recorded from PCA initiation until discontinuation. The total medication consumption will be expressed in milligrams (mg), and the duration of PCA use will also be recorded. Unit: mg. |
From PCA initiation to PCA discontinuation, within the first 72 hours after surgery.
|
|
Incidence of Adverse Events
時間枠:up to 3 months post-surgery
|
The incidence of adverse events will be assessed in both treatment groups. Recorded events will include gastrointestinal bleeding, renal impairment, cardiovascular events, and wound infection ect. |
up to 3 months post-surgery
|
協力者と研究者
スポンサー
出版物と役立つリンク
一般刊行物
- Lawal OD, Gold J, Murthy A, Ruchi R, Bavry E, Hume AL, Lewkowitz AK, Brothers T, Wen X. Rate and Risk Factors Associated With Prolonged Opioid Use After Surgery: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020 Jun 1;3(6):e207367. doi: 10.1001/jamanetworkopen.2020.7367.
- Hah JM, Bateman BT, Ratliff J, Curtin C, Sun E. Chronic Opioid Use After Surgery: Implications for Perioperative Management in the Face of the Opioid Epidemic. Anesth Analg. 2017 Nov;125(5):1733-1740. doi: 10.1213/ANE.0000000000002458.
- McNamara CA, Laurita J, Lambert BS, Sullivan TC, Clyburn TA, Incavo SJ, Park KJ. A multimodal intraosseous infusion of morphine and ketorolac decreases early postoperative pain and opioid consumption following total knee arthroplasty. Knee. 2023 Aug;43:129-135. doi: 10.1016/j.knee.2023.06.002. Epub 2023 Jul 1.
- Zhao C, Liao Q, Yang D, Yang M, Xu P. Advances in perioperative pain management for total knee arthroplasty: a review of multimodal analgesic approaches. J Orthop Surg Res. 2024 Dec 19;19(1):843. doi: 10.1186/s13018-024-05324-4.
- Hafeez K, Umar M, Desai V. Factors delaying mobilization after hip and knee arthroplasty. Int J Health Sci (Qassim). 2024 Sep-Oct;18(5):4-7.
- Haffar A, Fillingham YA, Breckenridge L, Gursay D, Lonner JH. Meloxicam versus Celecoxib for Postoperative Analgesia after Total Knee Arthroplasty: Safety, Efficacy and Cost. J Am Acad Orthop Surg Glob Res Rev. 2022 Apr 5;6(4):e22.00032. doi: 10.5435/JAAOSGlobal-D-22-00032.
- Ng JS, van der Werf B, Nicholson L, Farrington W, Young SW. The AAHKS Clinical Research Award: Intraosseous Regional Diclofenac for Postoperative Pain Management in Total Knee Arthroplasty. J Arthroplasty. 2025 Sep;40(S19):S18-S27. doi: 10.1016/j.arth.2025.05.013. Epub 2025 May 9.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- K20251066
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。